Eli Lilly and Co LLY · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500
1,354.00
-0.79%
Close of 6 Nov 2026, in USD
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $1.28trn
- Last close × shares
- Volume
- 3.8m
- Shares, 6 Nov 2026
- Price to earnings
- 61.8
- Dividend yield
- 0.47%
About Eli Lilly and Co
From its filings with the US Securities and Exchange Commission
Eli Lilly and Co is based in Indianapolis, Indiana and is incorporated in Indiana. Its shares trade on NYSE under the ticker LLY. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $65.18bn and net income of $20.64bn. At that date it held total assets of $112.48bn and shareholders' equity of $26.54bn.
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.
Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries.
In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.
In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Net product revenue $60.96bn · 93.5%
- Cardiometabolic Health $14.36bn · 22.0%
- Collaboration and other revenue $4.22bn · 6.5%
- Oncology $4.02bn · 6.2%
Latest on Eli Lilly and Co
Our reporting
- Eli Lilly and Co rises 3.10% in Friday's session
- Eli Lilly and Co rises 6.53% in Thursday's session
- Eli Lilly and Co rises 2.85% in Thursday's session
- Eli Lilly and Co rises 3.61% in Tuesday's session
- Eli Lilly and Co rises 3.60% in Thursday's session
- Eli Lilly and Co rises 3.64% in Wednesday's session
Next results
Due on 3 Feb 2027. Analysts expect earnings of 11.20 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Eli Lilly and Co's ticker?
Eli Lilly and Co trades as LLY on its US listing, under ISIN US5324571083.
What was Eli Lilly and Co's last closing price?
1,354.00 on 6 Nov 2026. The figure is in USD and is never converted.
When does Eli Lilly and Co next report results?
Results are expected on 3 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.